4.6 Article

Continuous positive airway pressure treatment and anxiety in adults with coronary artery disease and nonsleepy obstructive sleep apnea in the RICCADSA trial

Journal

SLEEP MEDICINE
Volume 77, Issue -, Pages 96-103

Publisher

ELSEVIER
DOI: 10.1016/j.sleep.2020.11.034

Keywords

Coronary artery disease; Obstructive sleep apnea; Anxiety; CPAP

Funding

  1. Swedish Research Council [521-2011-537, 521-2013-3439]
  2. Swedish HeartLung Foundation [20080592, 20090708, 20100664]
  3. V_astra G_otalandsregionen [ALFGBG-11538, ALFGBG-150801]
  4. Research fund at Skaraborg Hospital [VGSKAS-4731, VGSKAS-5908, VGSKAS-9134, VGSKAS-14781, VGSKAS-40271, VGSKAS116431]
  5. Skaraborg Research and Development Council [VGFOUSKB-46371]
  6. Heart Foundation of K_arnsjukhuset
  7. ResMed Foundation
  8. ResMed Ltd.

Ask authors/readers for more resources

The study showed that CPAP had no significant impact on anxiety in CAD patients with nonsleepy OSA. However, a trend of increased anxiety scores was observed in patients adhering to CPAP treatment at 3 months and 12 months, while patients who were non-adherent to CPAP showed a decrease in anxiety scores.
Background: Anxiety and obstructive sleep apnea (OSA) coexist among adults with coronary artery disease (CAD) following revascularization. Continuous positive airway pressure (CPAP) is the first line treatment of OSA patients with daytime sleepiness. The current study evaluated the effect of CPAP on anxiety in CAD patients with nonsleepy OSA. Methods: Two hundred forty-four revascularized CAD patients with nonsleepy OSA (apnea-hypopnea index >= 15/h, Epworth Sleepiness Scale score <10) were randomly assigned to CPAP or no-CPAP between 2005 and 2010. Zung Self-rating Anxiety Scale (SAS) was administered at baseline and after 3 and 12 months with higher scores suggesting more anxiety. Results: A total of 208 patients with complete SAS scores at baseline and 12-month follow-up were included (CPAP, n = 103; no-CPAP, n = 105). In the intention-to-treat analysis, CPAP had no significant effect on the SAS scores. On-treatment analysis revealed a significant increase in the median of delta SAS score (+3.75) after three months among the participants using the device 2.8 h/day or more while there was a decline in the median of delta SAS score (-1.25) in the non-adherent or no-CPAP group (p = 0.031). The increase in the SAS score (+1.25) in the adherent group, and the decline (-1.25 points) in the non-adherent/no-CPAP group remained significant after one year (p = 0.011). Baseline SAS score predicted non-adherence [adjusted odds ratio 1.11; 95% confidence interval (CI) 1.04-1.18; p = 0.003], and there was an association between the increase in the SAS scores and accumulated CPAP hours/day [standardized 13 = 0.144 (95% CI 0.005-0.695), p = 0.047]. Conclusion: Our results suggest that anxiety should be considered in the management of CAD patients with nonsleepy OSA following revascularization. (C) 2020 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available